Skip to main content

Table 3 Presentation and comparisons of treatments, outcomes, and symptoms

From: Comparison of the clinical presentation across two waves of COVID-19: a retrospective cohort study

  

Wave

 

Critical disease

 
 

All patients (N = 311)

Wave 1 (N = 157)

Wave 2 (N = 154)

p-value

Yes (N = 54)

No (N = 257)

p-value

Treatment and outcomes

       

 Critical disease, N/total N (%)

54/311 (17.20)

45/157 (28.66)

9/154 (5.84)

 < 0.0005

   

 Fatal disease, N/total N (%)

31/311 (9.97)

25/157 (15.92)

6/154 (3.90)

 < 0.0005

31/54 (57.41)

  

 ICU care, N/total N (%)

31/311 (9.97)

25/157 (15.92)

6/154 (3.90)

 < 0.0005

31/54 (57.41)

  

 Days at ICU, median (IQR)

12 (4–20)

12 (5–18)

16 (2–45)

0.62

12 (4–20)

  

 Oxygen, N/total N (%)

168/311 (54.02)

91/157 (57.96)

77/154 (50.00)

0.17

52/54 (96.30)

116/257 (45.14)

 < 0.0005

 Days with oxygen supplement, median (IQR) N = 168

5 (2–11)

8 (3–12)

4 (2–7)

0.0042

10 (5–19)

4 (2–8)

 < 0.0005

 Mechanical ventilation, N/total N (%)

24/311 (7.72)

20/157 (12.74)

4/154 (2.60)

0.001

24/54 (44.44)

  

 Days with mechanical ventilation, median (IQR) N = 24

14 (7–21)

13 (7–19)

28 (7.5–46.5)

0.49

14 (7–21)

  

 Length of hospitalization, median (IQR)

4 (0–9)

5 (1–13)

3 (0–7)

0.01

18 (9–27)

2 (0–6)

 < 0.0005

 Long hospitalization, N/total N (%)

83/311 (26.69)

54/157 (34.39)

29/154 (18.83)

0.002

45/54 (75.93)

42/257 (16.34)

 < 0.0005

 Days from onset of symptoms to admission, median (IQR) N = 292

4 (2–8)

6 (2–9)

3 (1–6)

0.0071

2 (1–7)

5 (2–8)

0.04

 Readmission, N/total N (%)

62/311 (19.94)

28/157 (17.83)

34/154 (22.08)

0.35

12/54 (22.22)

50/257 (19.46)

0.64

Symptoms N/total N (%)

       

 Fever

216/311 (69.45)

125/157 (79.62)

91/154 (59.09)

 < 0.0005

45/54 (83.33)

171/257 (66.54)

0.015

 Runny nose

17/311 (5.47)

10/157 (6.37)

7/154 (4.55)

0.62

3/54 (5.56)

14/257 (5.45)

1

 Cough

175/311 (56.27)

112/157 (71.34)

63/154 (40.91)

 < 0.0005

35/54 (64.81)

140/257 (54.47)

0.16

 Sore throat

30/311 (9.65)

18/157 (11.46)

12/154 (7.79)

0.34

4/54 (7.41)

26/257 (10.12)

0.80

 Shortness of breath/dyspnea

176/311 (56.59)

105/157 (66.88)

71/154 (46.10)

 < 0.0005

47/54 (87.04)

129/257 (50.19)

 < 0.0005

 Headache

60/311 (19.29)

24/157 (15.29)

36/154 (23.38)

0.071

11/54 (20.37)

49/257 (19.07)

0.83

 Muscle aches/myalgia

63/311 (20.26)

34/157 (21.66)

29/154 (18.83)

0.54

9/54 (16.67)

54/257 (21.01)

0.47

 Diarrhea

58/311 (18.65)

30/157 (19.11)

28/154 (18.18)

0.89

8/54 (14.81)

50/257 (19.46)

0.56

 Malaise

81/311 (26.05)

38/157 (24.20)

43/154 (27.92)

0.46

17/54 (31.48)

64/257 (24.90)

0.32

 Nausea

43/311 (13.83)

14/157 (8.92)

29/154 (18.83)

0.013

3/54 (5.56)

40/257 (15.56)

0.053

 Vomiting

32/311 (10.29)

15/157 (9.55)

17/154 (11.04)

0.71

2/54 (3.70)

30/257 (11.67)

0.088

 Tiredness

66/311 (21.22)

40/157 (25.48)

26/154 (16.88)

0.064

16/54 (29.63)

50/257 (19.46)

0.096

  1. The distributions of treatments, outcomes, and symptoms were presented for all hospitalized patients. Treatments, outcomes, and symptoms are compared between patients admitted in waves 1 and 2 in addition to patients with and without critical COVID-19 disease
  2. Bold p-values specify significance < 0.05
  3. IQR interquartile range, N number, ICU intensive care unit